Rafferty Asset Management LLC Acquires 61,464 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rafferty Asset Management LLC boosted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 67.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 152,454 shares of the biopharmaceutical company's stock after acquiring an additional 61,464 shares during the period. Rafferty Asset Management LLC owned approximately 0.23% of Celldex Therapeutics worth $3,853,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CLDX. Deep Track Capital LP bought a new position in Celldex Therapeutics during the fourth quarter worth about $38,919,000. Point72 Asset Management L.P. lifted its holdings in Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after acquiring an additional 847,264 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after acquiring an additional 676,771 shares in the last quarter. American Century Companies Inc. lifted its holdings in Celldex Therapeutics by 46.5% during the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after acquiring an additional 193,093 shares in the last quarter. Finally, Crestline Management LP lifted its holdings in Celldex Therapeutics by 114.0% during the fourth quarter. Crestline Management LP now owns 295,354 shares of the biopharmaceutical company's stock worth $7,464,000 after acquiring an additional 157,366 shares in the last quarter.

Celldex Therapeutics Stock Performance

CLDX opened at $20.45 on Monday. The business's 50-day simple moving average is $18.91 and its 200 day simple moving average is $22.55. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The firm has a market capitalization of $1.36 billion, a PE ratio of -7.96 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. On average, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on CLDX. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Morgan Stanley dropped their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. UBS Group dropped their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, The Goldman Sachs Group dropped their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Celldex Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.